Kadmon Drug Patent Portfolio
Kadmon owns 1 orange book drug protected by 6 US patents Given below is the list of Kadmon's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12097202 | Methods of administering Belumosudil for treatment of chronic graft versus host disease | 14 Jul, 2042 | Active |
| US11311541 | Treatment of GVHD | 09 Apr, 2035 | Active |
| US8357693 | Pharmacokinetically improved compounds | 20 Jun, 2034 | Active |
| US10183931 | Rho kinase inhibitors | 07 Oct, 2033 | Active |
| US10696660 | Rho kinase inhibitors | 07 Oct, 2033 | Active |
| US9815820 | Rho kinase inhibitors | 07 Oct, 2033 | Active |
Latest Legal Activities on Kadmon's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kadmon.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jul, 2024 | US8357693 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US8357693 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2023 | US10696660 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8357693 |
|
Electronic Review
Critical
| 01 Jun, 2023 | US10696660 |
| Mail Certificate of Correction Memo | 31 May, 2023 | US10696660 |
| Post Issue Communication - Certificate of Correction | 30 May, 2023 | US10696660 |
| Certificate of Correction Memo | 26 May, 2023 | US10696660 |
|
Electronic Review
Critical
| 25 May, 2023 | US10183931 |
|
Electronic Review
Critical
| 25 May, 2023 | US9815820 |
| Mail Certificate of Correction Memo | 24 May, 2023 | US9815820 |
| Mail Certificate of Correction Memo | 24 May, 2023 | US10183931 |
| Certificate of Correction Memo | 23 May, 2023 | US10183931 |
| Post Issue Communication - Certificate of Correction | 23 May, 2023 | US9815820 |
| Post Issue Communication - Certificate of Correction | 23 May, 2023 | US10183931 |
Kadmon Drug Patents' Oppositions Filed in EPO
Kadmon drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 28, 2023, by Elkington And Fife Llp. This opposition was filed on patent number EP13843426A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP13843426A | Feb, 2023 | SANDOZ AG | Granted and Under Opposition |
| EP13843426A | Feb, 2023 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
Kadmon's Family Patents
Kadmon Drug List
Given below is the complete list of Kadmon's drugs and the patents protecting them.
1. Rezurock
Rezurock is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12097202 | Methods of administering Belumosudil for treatment of chronic graft versus host disease |
14 Jul, 2042
(16 years from now)
| Active |
| US11311541 | Treatment of GVHD |
09 Apr, 2035
(9 years from now)
| Active |
| US8357693 | Pharmacokinetically improved compounds |
20 Jun, 2034
(8 years from now)
| Active |
| US10183931 | Rho kinase inhibitors |
07 Oct, 2033
(7 years from now)
| Active |
| US10696660 | Rho kinase inhibitors |
07 Oct, 2033
(7 years from now)
| Active |
| US9815820 | Rho kinase inhibitors |
07 Oct, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rezurock's drug page